| Jason Eskew, DO | |
|
801 Oak Ridge Tpke, Oak Ridge, TN 37830-6916 | |
| (865) 483-3172 | |
| Not Available |
| Full Name | Jason Eskew |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 801 Oak Ridge Tpke, Oak Ridge, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558700526 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2997 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Tn Medical Center Home Care Services | Knoxville, TN | Home health agency |
| Methodist Medical Center Of Oak Ridge | Oak ridge, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group, Pllc | 2860396330 | 485 |
News Archive
Researchers from the University of Leicester have developed an online tool which presents a variety of measures that quantify the survival of patients with cancer from different perspectives.
The Supreme Court upheld the core of President Obama's health care overhaul, ruling that the government can require all Americans to obtain health insurance or pay a penalty.
Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American Diabetes Association's 70th Annual Scientific Sessions (ADA).
Valeant Pharmaceuticals International, Inc. announced today that Valeant's subsidiaries, Valeant Pharmaceuticals North America LLC (VPNA) and Valeant International (Barbados) SRL (VIB), have signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
› Verified 8 days ago
| Entity Name | Summit Medical Group, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659090298 PECOS PAC ID: 2860396330 Enrollment ID: O20031125000793 |
News Archive
Researchers from the University of Leicester have developed an online tool which presents a variety of measures that quantify the survival of patients with cancer from different perspectives.
The Supreme Court upheld the core of President Obama's health care overhaul, ruling that the government can require all Americans to obtain health insurance or pay a penalty.
Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American Diabetes Association's 70th Annual Scientific Sessions (ADA).
Valeant Pharmaceuticals International, Inc. announced today that Valeant's subsidiaries, Valeant Pharmaceuticals North America LLC (VPNA) and Valeant International (Barbados) SRL (VIB), have signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason Eskew, DO 1225 E Weisgarber Rd, Suite 200, Knoxville, TN 37909-2604 Ph: (865) 584-4747 | Jason Eskew, DO 801 Oak Ridge Tpke, Oak Ridge, TN 37830-6916 Ph: (865) 483-3172 |
News Archive
Researchers from the University of Leicester have developed an online tool which presents a variety of measures that quantify the survival of patients with cancer from different perspectives.
The Supreme Court upheld the core of President Obama's health care overhaul, ruling that the government can require all Americans to obtain health insurance or pay a penalty.
Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American Diabetes Association's 70th Annual Scientific Sessions (ADA).
Valeant Pharmaceuticals International, Inc. announced today that Valeant's subsidiaries, Valeant Pharmaceuticals North America LLC (VPNA) and Valeant International (Barbados) SRL (VIB), have signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
› Verified 8 days ago
Alex M Alexander, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 114 Dover Ln, Oak Ridge, TN 37830 Phone: 865-482-9911 | |
Dr. David Worrell Seay, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 100 Vermont Ave, Oak Ridge, TN 37830 Phone: 865-482-1777 Fax: 865-482-1030 | |
Dr. Toral Bharat Pattni, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Vermont Ave, Oak Ridge, TN 37830 Phone: 865-482-1777 Fax: 865-482-1030 | |
Pamela A Bridgeman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 Oak Ridge Tpke, Oak Ridge, TN 37830 Phone: 865-483-3172 | |
Dr. David Ross Compton, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Vermont Ave, Oak Ridge, TN 37830 Phone: 865-482-1777 Fax: 865-482-1030 | |
Sonali Deo, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 Oak Ridge Tpke, Oak Ridge, TN 37830 Phone: 865-483-3172 Fax: 833-908-2163 | |
Dr. Elizabeth Tenaglia Azel, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 100 Vermont Ave, Oak Ridge, TN 37830 Phone: 865-482-1777 Fax: 865-482-1030 |